JAMA : the journal of the American Medical Association
-
Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice. ⋯ Advances in treatment and prevention of HIV continue to improve outcomes, but challenges and opportunities remain.
-
The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. ⋯ Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.